Many tumors are characterized by large genomic heterogeneity and it remains unclear to what extent this 30 impacts on protein biomarker discovery. Here, we quantified proteome intra-tissue heterogeneity (ITH) 31 based on a multi-region analysis of 30 biopsy-scale prostate tissues using pressure cycling technology and 32 SWATH mass spectrometry. We quantified 8,248 proteins and analyzed the ITH of 3,700 proteins. The 33 level of ITH varied significantly depending on proteins and tissue types. Benign tissues exhibited 34 generally more complex ITH patterns than malignant tissues. Spatial variability of ten prostate biomarkers 35 was further validated by immunohistochemistry in an independent cohort (n=83) using tissue microarrays. 36
Introduction 42
During the last decade numerous new cancer treatment options have been developed. Their 43 optimal application, however, requires better molecular characterization of the tumors with the aim of 44 developing biomarkers matching the specific tumor to the best available therapy. Some cancer types, such 45 as prostate cancer, still suffer from an 'over treatment problem', i.e. radical therapy such as removal of 46 the organ in unnecessary cases due to uncertain diagnosis. These problems persist despite the recent 47 progress in genomic, transcriptomic, and proteomic profiling of tumors. In contrast to the standardization 48 of histopathological diagnostic categories, tumor grading, and standards of reporting, molecular testing is 49 still underexploited in routine diagnostics of localized prostate cancer cases. A recent review about 50 biomarkers in prostate cancer (Kristiansen, 2018) has highlighted the need to consider intra-tissue 51 heterogeneity (ITH) in each individual case for successful molecular testing. ITH is of high clinical 52
relevance. For instance, a tumor may contain a small sub-population of cells with primary resistance, 53 leading to incomplete response to treatment or early recurrence (Murtaza, Dawson et al., 2015) . High 54 degree of Gleason score, DNA ploidy, and PTEN expression have been observed in prostate tumors (Cyll, 55 Ersvaer et al., 2017). Thus, it remains a challenge to optimize clinical decisions based on single biopsies 56 High-throughput antibody-based immunohistochemistry staining has been applied to tissue sections 76 (Uhlen, Fagerberg et al., 2015) . However, such data are semi-quantitative and limited in scope by the 77 availability of suitable antibodies. Label-free shotgun proteomics has been used to explore in-depth the 78 proteome of multiple regions of tumor tissues (Wisniewski, Ostasiewicz et al., 2012) . However, due to 79 the inherent technical limitations, the method is not suitable to systematically explore ITH at high sample-80 throughput and high spatial resolution, which is essential to achieve adequate spatial resolution (Domon 81 & Aebersold, 2010). Single-cell proteomics using mass cytometry is another promising technology 82 allowing quantification of protein levels in thousands of individual cells. However, the technique at 83 present only measures 10s of proteins per sample (Giesen, Wang et al., 2014) . 84
We have recently developed a mass spectrometry-based proteomics method, i.e. pressure cycling 85 technology and sequential windowed acquisition of all theoretical fragment ion mass spectra (PCT-86 SWATH) (Guo, Kouvonen et al., 2015b) , which supports highly reproducible and accurate quantification 87 of a few thousand proteins from biopsy-scale tissue samples at high throughput. This is accomplished by 88 the integration into a single platform of optimized sample preparation, mass spectrometric and 89 computational elements. To generate mass spectrometry-ready peptide samples from tissue samples we 90 adopted PCT to lyse the tissues, extract proteins and digest them into peptides in a single tube under 91 precisely controlled conditions (Powell, Lazarev et al., 2012) . To analyze the resulting peptide samples, 92
we used SWATH-MS, a massively parallel targeting mass spectrometry method (Gillet, Navarro et al., 93 2012) . In SWATH-MS all MS-measurable peptides in a sample are fragmented and periodically recorded 94 over a single dimension of relatively short chromatography (Gillet et al., 2012) . The net result of this 95 technique is a single digital file that contains fragment ions of all mass spectrometry-detectable peptides, 96 from which peptides and proteins are identified and quantified post acquisition, via a targeted data 97 analysis strategy (Gillet et al., 2012 , Röst, Rosenberger et al., 2014 . 98
In this study, we approached proteomic ITH for prostate cancer tissues by PCT-SWATH-based 99 multi-region proteomic analysis of 60 biopsy-level tissue samples from three prostate cancer patients. We 100 then computed the technical and spatial biological variation for each measured protein in different types 101 of tissues and different patients, and established a proteome-scale landscape of protein ITH in benign and 102 malignant prostate tissues. Our data revealed distinct ITH patterns of prostate cancer biomarkers that were 103 further independently validated using immunohistochemistry (IHC) in an independent set of 83 patients. 104
RESULTS 106 107

Study design for quantifying proteomic variability 108
We designed a study to quantify spatial proteomic variability in multiple regions of malignant and 109 matching benign prostate tissues using the PCT-SWATH-MS platform (Guo, Kouvonen et al., 2015a) . 110
We assumed that the total proteomic variability observed in the sample cohort was composed of technical 111 and biological variation, the latter including inter-patient, inter-tissue and intra-tissue variation. To open 112 the possibility to partition the overall observed variability into its possible sources, we obtained tissue 113 samples from multiple regions of prostatectomy specimens as illustrated in Figure 1 . Each sample was a 114 tissue punch biopsy consisting of a cylinder of 1 mm diameter and about 3 mm length that was derived 115 from fresh frozen tissue blocks using a core needle. Samples were obtained from prostatectomy 116 specimens in three individuals diagnosed with adenocarcinoma (ADCA) of the prostate. . 1 ). In total, 12 benign prostatic hyperplasia (BPH) and 18 ADAC tissue samples were obtained. One 120 of the three individuals had a mixed acinar and ductal ADAC, and both subtypes were included in the 121 study to measure the variation resulting from morphologically distinct subtypes. The other two patient 122 samples displayed acinar ADCA by histologic means. Each tissue type (malignant versus benign) of each 123 patient was sampled three to six times resulting in a total of 30 biological samples. Each sample was 124 processed by PCT-SWATH in duplicate to evaluate the technical variation of the proteomic analysis ( Fig.  125 Thereby, we minimized the possibility that peptide intensity variation was not due to protein abundance 140 changes, but due to post-translational modifications or other artifacts (see Methods) (Picotti, Ziza et al., 2013). We then corrected batch effects in the dataset by subtracting the average signal of each 142 protein per batch. After batch correction, most technical replicates grouped together by unsupervised 143 clustering based on the abundance of all proteins (Supplementary Fig. 2) . 144 145
Quantification of spatial proteomic heterogeneity 146
Our estimates of proteomic ITH are based on the notion that the signal variation between two 147 samples is due to a combination of biological and technical factors. Since the biological variation is not 148 directly quantifiable, we estimated biological variance by subtracting the technical variance from the total 149 observed punch-to-punch variance. 150
The technical variance was estimated by calculating the dispersion between two technical 151 replicates for each sample (independent protein digests from the same punch measured separately), i.e. 152 generating 30 initial technical variance estimates per protein before averaging them (see Methods for 153 details). This strategy produced seven technical variance estimates for all pairs of patient / tissue type 154 (three normal tissue regions, three acinar tissue regions, and one ductal tissue region, Fig. 1 ). Pairwise 155 correlations of these seven independent estimates showed that technical variances were consistently 156 positively correlated, with a median correlation of 0.572 ( Fig. 2A) . Likewise, we analyzed the same type 157 of correlation for the total punch variances. Like the technical variance, independent estimates of the total 158 variance were also highly correlated, albeit with a slightly lower median correlation of 0.302, suggesting 159 that the technical variance was more robust and less dependent on the specific sample than the total 160 variance and the biological variance ( Fig. 2B) . Thus, as expected, the technical variance of a protein was 161 mostly determined by its physico-chemical properties, whereas total variance varied in different tissue 162 samples probably due to biological factors. Further, technical variance of log-transformed intensities was 163 independent of the mean log-intensity ( Supplementary Fig. 3 ), suggesting that the same estimate of 164 technical variance could be used at high and low protein concentrations. Subsequently, we averaged the 165 seven estimates of technical variance per protein to obtain a single, robust estimate of each protein's 166 technical variance. 167
Having established that our estimates of total variances and technical variances are robust, we 168 next computed biological variances by subtracting each protein's technical variance from its total 169 variance between punches of the same patient and tissue type (see Methods). This yielded an estimate of 170 intra-tissue biological variances of protein abundance which can be interpreted as the degree of proteomic 171 ITH. The technical and total variances were independently estimated, which makes it numerically 172 possible that the technical variance can be larger than the total variance of a specific set of punches.
Indeed, for 183 proteins (4.9%) the estimated technical variance was larger than the total variance 174 ( Supplementary Fig. 4) . These were mostly the proteins with very low total variance. We could not 175 rigorously quantify the biological variances of these proteins, nevertheless, we assumed that most of them 176 would have comparably low biological variances. Proteins with technical variances higher than total 177 variances were excluded from most subsequent analyses. 178
Next, we compared the biological variances within a tissue with the biological variance between 179 tissue types (benign versus malignant; termed inter-tissue) and between patients ( Fig. 3) . Inter-tissue and 180
inter-patient variances were obtained by first averaging protein intensities from punches of the same 181 tissue or patient, respectively (see Fig. 1A and Methods). Our data showed that the biological variance 182 between punches within the same tissue (i.e. intra-tissue variance) is of similar magnitude as the variation 183 of average intensities between tissues and patients, indicating a high degree of protein ITH (Fig. 3A) . 184
Further, the protein variances between patients, tissue, and within tissue were significantly correlated 185 ( Fig. 3B-D) . Thus, a protein with large intra-tissue variation is also likely to vary across tissues and 186 between the three patients. 187
188
Classification of proteins based on their intra-tissue variability 189
To characterize ITH in different tissue types, we compared the biological variance of each protein 190 in benign and malignant prostate tissues, and quantified the variability of 3,517 proteins in BPH and 191 ADCA tissue samples ( Supplementary Table 5 ). Interestingly, we observed a strong dependence of the 192 variability of some proteins on the tissue type. We then classified the thus quantified proteins into five 193 groups based on their biological variance patterns in the different sample types ( Fig. 4A) . Group no. 1 194 consisted of 100 proteins that were always robust and generally showed little intra-tissue variation in 195 benign and malignant prostate tissues. Group no. 2 consisted of 339 proteins that varied substantially 196 more in benign tissues compared to malignant tissues. Group no. 3 consisted of 93 proteins that varied 197 more strongly in malignant tissues compared to benign tissues. Group no. 4 contained 365 proteins that 198 had high intra-tissue variance in both malignant and benign tissues, while group no. 5 contained the 199 remaining 2,620 proteins with intermediate variability. Remarkably, the top three most variable proteins 200 in BPH are three proteins known or used in the diagnosis of prostate tumors, including prostate-specific 201 antigen (PSA/KLK3), prostatic acid phosphatase (PAP/ACPP) and Desmin (DES). PSA is an androgen-202 regulated kallikrein family serine protease, that is produced by the secretary epithelial cells in acini and 203 ducts of prostate glands (Balk, Ko et al., 2003) . The secreted PSA, originated from prostate tissues, is the 204 most commonly used, blood-based biomarker for prostate cancer (Hayes & Barry, 2014) . However, PSA 205 screening has remained controversial because of uncertainty surrounding its benefits and risks and the 206 optimal screening strategy (Barry, 2009) . Our data showed that PSA in situ was most variable in BPH but 207 more stable in ADCA tissues. Since PSA is regulated by androgen, this indicates androgen-driven 208 malignant growth of prostate tumor cells. PAP is a non-specific tyrosine phosphatase and a well-studied 209 tumor suppressor for PCa. PAP has already been used in immunotherapy regimens against PCa (Di 210
Lorenzo, Buonerba et al., 2011) and is the second most variable protein in BPH after PSA. The variability 211 of PAP expression was relatively high in ADCA samples, but lower than its variability in BPH samples. myofibroblast/fibroblast mix with a significant decrease or complete loss of fully differentiated smooth 216 muscle, whereas normal prostate stroma is predominantly smooth muscle (Tuxhorn, Ayala et al., 2002) . 217
Given the known heterogeneous composition of myoglandular hyperplasia (i.e. BPH) out of glandular and 218 stromal (smooth muscle) elements, the higher variability of DES expression in BPH compared to PCa is 219 not surprising. 220
To further investigate the protein variability classes, we then performed a gene ontology (GO) 221 enrichment analysis ( Fig. 4B) . As expected, stable proteins of group no. 1 were enriched for basic cellular 222 functions that were required irrespective of the tissue state, such as energy metabolism (Fig. 4B) . Proteins We further investigated the biological variation of selected proteins from the PCT-SWATH 260 analysis using a complementary technology in an independent, larger cohort. We constructed a tissue 261 microarray (TMA) using benign and malignant (ADCA) prostate tissues from 83 additional patients and 262 established IHC assays to measure the expression of ten representative proteins in the various ITH groups 263 identified from the PCT-SWATH results, including ACTR1B, DES, PSA, GDF15 as shown in Fig. 5 , as 264 well as ACPP, ABCF1, NUP93, CUTA, CRAT, and FSTL1 ( Supplementary Fig. 5 ). This set of 265 validation proteins contains some well-established markers for prostate cancer in order to elucidate their 266 variability within benign and tumorous tissue specimens. The stained TMAs contained duplicate tissue 267 cores of 48 ADCA and 35 BPH samples. The heterogeneity of proteins was evaluated based on an 268 immunoreactivity score computed from duplicate tissue spots and measured by the Pearson correlation 269 coefficient between the two spots for BPH and ADCA respectively ( Fig. 5) . Thus, a high Pearson 270
correlation score indicates a homogeneous distribution of the respective protein in the TMAs (i.e. low 271 ITH). We found that the degree of ITH determined in the three patients by PCT-SWATH was well 272 validated in the independent cohort. ACTR1B is an actin-related protein in the dynamin complex to 273 construct cytoskeleton. This house-keeping protein exhibited a very high degree of correlation in both 274 BPH (r = 0.96) and ADCA (r = 0.80) samples, serving as a positive control. In the TMA cohort, DES 275 was more variable in BPH (r = 0.51) than in ADCA (r = 0.67), which is consistent with proteomics data. 276
Our TMA data demonstrated that in BPH samples, PSA was found only in the glandular tissue, and 277 expressed more heterogeneous than in ADCA samples, with blood PSA levels being a non-specific 278 biomarker for PCa. Growth/differentiation factor 15 (GDF15) is a stress-induced cytokine belonging to 279 the transforming growth factor beta superfamily (Vanhara, Hampl et al., 2012) . This protein is expressed 280 in highly complex forms with distinct biological functions related to immunity. In various tumors 281 including prostate cancer, GDF15 interacts with the extracellular matrix and promotes tumor progression 282 and metastasis (Vanhara et al., 2012) . We found GDF15 to be expressed at relatively low levels in BPH 283 with a low degree of ITH probably due to inflammatory changes of glandular architecture followed by 284 stromal tissue increase in BPH (Vanhara et al., 2012) . In the ADCA samples, GDF15 expression was 285 elevated with a high degree of variation, indicating complex interactions between tumor cells and the 286 microenviroment via modulators including GDF15. The high variability of ACPP in BPH samples was 287 also confirmed in this cohort. Proteins grouped as medium heterogeneity including ABCF1, NUP93, 288 CUTA, CART, and FSTL1 displayed consistent heterogeneity patterns after manual inspection of the 289 TMA data. Taken together, we observed significant correlations between the heterogeneity measured in This study investigated the spatial variability of the prostate proteome, which serves as a basis for 296 better understanding the biology of PCa protein biomarkers. Protein biomarkers including PSA and 297 GDF15 have been well studied in PCa, however, their spatial expression in prostate tissues has not been 298 systematically studied. ITH has been studied at the morphologic and genomic level in diverse cancers, enabling analysis of single cells from tissue samples will be desirable to quantify spatial ITH at higher 319 spatial resolution in future studies. 320
The main goal of this study was not to discover new protein biomarkers; instead we aimed to 321 characterize the spatial ITH of the prostate proteome and investigate whether the ITH influences the 322 utility of protein biomarkers and candidates. Our data contributed to the understanding of the following 323 prostate cancer biology. First, we systematically reported the degree of ITH of 3,700 proteins in prostate 324 tissues. Although some of these proteins are widely used in clinic, their expression pattern in prostate 325 tumors was unclear. We found PSA preferentially variable in BPH, while GDF15 tended to vary in 326 different tumor regions. This finding, together with the ITH pattern of eight more clinically relevant 327 protein biomarkers, were further investigated and confirmed in an independent cohort of 83 PCa patients 328 using TMA technology. This additional cohort analysis not only confirm that the PCT-SWATH 329 technology is a valid and practical extension of IHC and TMA for proteome-scale ITH analysis of clinical 330 tissue samples, but also consolidated the spatial variability of these proteins in prostate tissues, providing 331 guidance for clinical application of these proteins as biomarkers. We found protein ITH patterns to vary 332 between tissue types due to their biological functions and interplay with the microenvironment. 333
Second, the data also shed light on the heterogeneity of multiple biochemical pathways. 334
Interestingly, benign tissue displayed a high degree of variability in immunity-related signaling pathways, 335
whereas tumor tissues, characterized by enhanced proliferation and DNA-damage, exhibited high degree 336
of heterogeneity in several DNA damage response pathways, suggesting that spatially variable DNA 337 repair pathways probably contributed to genomic heterogeneity during the evolution of prostate cancers. 338
Further, we found that the degree of intra-tissue variability of multiple pathways was slightly higher in 339 benign specimens compared to malignant tissues (Fig. 4) , which may be due to the more complex 340 structure of healthy tissues involving a larger number of distinct cell types, while in tumorous tissues 341 most cell types are replaced by tumor cells.
The observed intra-tissue protein variability patterns have implications that extend beyond the 343 present study to protein biomarker studies in general and have specific significance for biomarker studies 344 in the context of personalized medicine, where sample availability is generally sparse. Our data suggest 345 that the variation of some protein levels between patients is similar in magnitude to the variation within a 346 single prostate. These findings underline the significance of low intra-tissue variability as an important 347 property of a clinical protein biomarker. In fact, the observed variability patterns provide a rational 348 explanation why some previously published tissue biomarker studies did not produce concordant results. 349
Similar conclusions were drawn in an earlier study, in which the abundance variability of plasma proteins 350 was analyzed in a twin cohort (Liu, Buil et al., 2015) . The data indicated that those biomarker candidates 351 that were proposed in the literature and eventually approved for clinical use showed low levels of 352 variability derived from genetic differences in a population. In contrast, biomarker candidates proposed in 353 the literature that showed a high degree of genetically caused abundance variation in a population were 354 rarely validated. Our data add a new perspective to this problem: a candidate biomarker may show high 355 variability between patients when quantified using single needle biopsies per patient. However, the 356 tumor-wide average concentrations may not be substantially different, and the true cause of the apparent 357 inter-patient variability may be ITH, rather than rooted in the biochemical difference between normal and 358 tumor tissues. Therefore, we suggest that intra-tissue variability of a protein or a pathway be used as an 359 important criterion for the assessment of protein biomarker candidates, in addition to other parameters 360 such as expression level and biochemical function. Including more biological replicates per patient to 361 average out protein ITH or increasing patient numbers to account for variability may not always be 362 possible. Thus, our work provides an important lead as to how ITH can be tackled even for small patient 363 and sample numbers in clinically realistic scenarios.
MATERIALS & METHODS 365 366
Patients and samples for PCT-SWATH analyses 367
The prostates from three patients after prostatectomy were cut into tissue sections (thickness: 368 about 3 mm). Fresh BPH and ADCA tissue sections were frozen and embedded in O.C.T.. The tissue 369 were examined by trained pathologists and graded similarly according to the Gleason system as shown in 370 following the 32-fixed-size-window scheme as described previously with a 5600 TripleTOF mass 394 spectrometer (Sciex) and a 1D+ Nano LC system (Eksigent, Dublin, CA). The LC gradient was 395 formulated with buffer A (2% acetonitrile and 0.1% formic acid in HPLC water) and buffer B (2% water 396 and 0.1% formic acid in acetonitrile) through an analytical column (75 μm × 20 cm) and a fused silica BioResources, Auburn, CA, USA). Peptide samples were separated with a linear gradient of 2% to 35% 399 buffer B over 120 min at a flow rate of 0.3 μl min −1 . Ion accumulation time for MS1 and MS2 was set at 400 100 ms, leading to a total cycle time of 3.3 s. 401 402 SWATH assays for prostate tissue proteome 403
We also analyzed unfractionated prostate tissue digests prepared by the PCT method using Data 404 Dependent Acquisition (DDA) mode in a tripleTOF mass spectrometer over a gradient of 2 hours as 405 described previously (Röst et al., 2014) . We spiked iRT peptides (Escher, Reiter et al., 2012) Altogether, we identified 160,442 peptides with <1% FDR. 418 419 Peptide quantification using OpenSWATH 420 SWATH files were analyzed using the prostate tissue proteome assay library described above and 421
OpenSWATH software as described previously (Röst et al., 2014) . Briefly, wiff files were converted into 422 mzXML files using ProteoWizard msconvert v.3.0.3316, and then mzML files using OpenMS (Sturm, 423 Bertsch et al., 2008) tool FileConverter. OpenSWATH was performed using the tool 424
OpenSWATHWorkflow with input files including the mzXML file, the TraML library file, and TraML 425 file for iRT peptides. The false discovery rate for peptide identification was below 0.1%. High confidence 426 peptide features from different samples were aligned using the algorithm TRansition of Identification 427
Confidence (TRIC) (version r238), which is available from 428 https://pypi.python.org/pypi/msproteomicstools or https://code.google.com/p/msproteomicstools/. The 429
following parameters for the feature_alignment.py are as follows: max_rt_diff = 30, method = 430 global_best_overall, nr_high_conf_exp = 2, target_fdr = 0.001, use_score_filter = 1. 431
Protein quantification 433
The concentration of each protein was quantified through the simultaneous measurement of 434 several peptides. To optimize the protein quantification, we developed a new computational method, 435 which combines maximally consistent peptides for each protein and excludes inconsistent (i.e. 436 uncorrelated) peptides (Picotti et al., 2013) . For example, variation of post-translational modifications 437 (PTM) would result in peptide level variation that is uncorrelated across samples, because mostly only 438 one of the two peptides would be affected by the PTM. (Picotti et al., 2013) . Given a set of peptides 439 unambiguously assigned to a single protein, consistent peptides were selected using the following 440 procedure: all pairwise correlations between all peptides of a protein across the samples were calculated 441 at first. Peptide pairs with a Pearson correlation coefficient (R) of at least 0.3 were determined, resulting 442 in clusters of correlated peptides. This procedure yielded one or more peptide clusters per protein. We 443 used the largest cluster of each protein and we quantified the protein's concentration as the average 444 intensity across the peptides in that cluster. The minimum cluster size was set to 2 and proteins without a 445 cluster of at least two correlated peptides were removed from the subsequent analysis. This procedure 446 resulted in very robust concentration estimates for 3,700 proteins with high correlation between technical 447 replicates (R ≥ 0.95) and no missing values. 448 449
Determining the biological variance between punches in a specific tissue (intra-tissue variance) 450
Measurements of protein abundance differences between individual punches are affected by a 451 combination of biological and technical factors. Thus, to quantify the biological variation between 452 punches we need to subtract the technical variance from the total variance, i.e. the combined variance due 453 to technical and biological factors. Estimating the biological variance of protein levels between punches 454 therefore requires estimates of the technical variance and the total variance. Intuitively, one would 455 estimate both variances using a standard approach such as ANOVA in a single statistical model. 456
However, technical replicates are paired because they come from the same punch and thus they are not 457 independent, whereas the total variance needs to be estimated across punches, i.e. involving partially 458 independent measurements. 459
Therefore we decided to separately estimate technical and total variances. Here, technical 460 variance was estimated from the dispersion of measurements between paired technical replicates and total 461 variance was estimated from the dispersion of measurements between independent punches from the 462 same specimen. Compared to an approach estimating both technical and total variance in a single 463 statistical model, our approach has the caveat that the two variance estimates can be inconsistent in the 464 sense that the estimated total variance can be smaller than the estimated technical variance. Obviously, 465 this happens only for those proteins where the technical noise is large compared to the biological 466 variance, in which case it is anyways impossible to reliably estimate the true biological variance (no 467 matter which statistical approach is taken). We therefore conservatively accept that in those cases we 468 cannot provide an estimate of the biological variance. However, we assume that in most of those cases the 469 biological variance will be small compared to the other proteins for which we could estimate a biological 470
variance. 471
In detail, the variances were estimated in the following way. 472
First, the protein concentrations (computed from peptide intensities as described above) were 473 log10-transformed. Next, protein concentrations were quantile normalized per sample. As the signal 474 distributions between non-tumorous (benign) and tumorous tissue (malignant: acinar and ductal) differed 475 significantly, the normalization was performed separately for each tissue type. For each protein, we 476 computed the technical variation for each sample and averaged the inter-replicate variance across all 30 477 samples (Tukey, 1977) . Since technical replicates are (obviously) paired, the technical variance was 478 estimated as the dispersion of the two replicates from their sample mean averaged across all punches (n = 479 30). Thus, the technical variance VARTECH of protein i was estimated as: 480
with , and , being the two technical replicates (a and b) of the protein level measurements 482 from punch j. In this case, no batch correction was performed, because batch correction would reduce the 483 technical variance (technical replicates were always in different batches), which might lead to 484 underestimation of the technical variance. The final estimate of technical variances was computed after 485 removing outliers above and below the 1.5*IQR of 30 samples based on Tukey's method (Tukey, 1977) . 486
The total variances between punches (i.e. the combined variance from technical noise and 487 biological variance) were initially computed for each batch separately. Thus, variation among punches 488 from the same specimen (same patient p and same tissue type t) were averaged. Finally, total variances 489 VARTOT between punches were averaged across batches. 490
Where ( , ) denotes all punches j from patient p and tissue t (i.e. either benign, acinar, or 492 ductal). The indices a and b denote the two technical replicates, as above. Thus, total variances were 493 estimated purely from deviations within batches and are (unlike technical variances) not affected by 494 batch-to-batch variation. As a consequence, technical variances are biased towards larger values 495 compared to total variances. This approach is conservative in the sense that it minimizes the number of 496 proteins that are falsely classified as having variable concentrations within tissues. Thus, this approach 497 will likely underestimate the true number of proteins with large biological intra-tissue variance. Given the total variance and technical variance, the biological variance VARBIO of protein i was computed as 499 follows: 500
This scheme generated seven independent estimates of total variance per protein: four for the 502 patients no. 1 and no. 2 (benign and malignant acinar tissues) and three for patient no. 3 (benign, acinar, 503 and ductal). The intra-tissue variance shown in Figure 4 is the average biological variance of a given 504 protein across all patients and tissue types. The tissue-specific variances used for Figure 5 are the average 505 variances across the patients for the respective tissues (benign, acinar, ductal). The biological variance in 506 tumor was estimated as the average of all acinar and the ductal (patient 3) tumor regions. 507 508
Grouping of proteins and pathways based on their variability 509
In cases where the estimated technical variance is greater than the estimated total variance, 510 subtracting the technical from the total variance yields a negative 'variance estimate' (Supplementary  511   Fig 4) . Because these negative 'variances' are the result of our imperfect variance estimates, the 512 distribution of these values can be used to quantify the inherent uncertainty in our estimates of the 513 biological variance. Thus, we can use the distribution of the absolute values (the 'mirror distribution' into 514 the positive range) as a background distribution for the Null hypothesis that the true biological variance is 515 indistinguishable from zero (or: that the total observed variance is exclusively due to technical variance). 516
Based on this approach, 797 proteins had p-values below 0.01 and were thus classified as biologically 517 variable proteins (i.e. significantly variable within the same specimen). These797 variable proteins were 518 further sub-classified as follows: if the ratio of biological variance in benign to biological variance in 519 tumor was above 2 they were classified as "variable in non-tumor" (339 proteins); if the ratio of 520 biological variance in tumor to biological variance in normal was above 2, proteins were classified as 521 "variable in tumor" (93 proteins); 365 proteins with similar variances in both tissue types (i.e. not 522 different by more than a factor of 2) were classified as "variable in non-tumor and tumor". Stable proteins 523 were defined by choosing the 100 proteins with the lowest biological variance. Remaining proteins, which 524
were not assigned to any of the above four groups, were classified as "medium heterogeneity" proteins. 525
Note that our computation of empirical p-values for determining variable proteins is not critical 526 for the conclusions. If we had simply chosen the top 200 most variable proteins (as the basis for groups 1- 
Gene Set Enrichment Analysis 531
Gene Ontology (GO) enrichment of proteins was performed using topGO, which takes the 532 topology of the ontology into account. The enrichment analysis was carried out by using Fisher's exact 533 test with the background of measured proteins in this study. We excluded GO terms with less than 10 534 proteins and with more than 300 proteins from the analysis (the former are too small, the latter are too 535 generic). Further, we reported only GO terms that had at least 4 proteins enriched (overlapping). 536
Intra-tissue heterogeneity of entire biochemical pathways was determined according to the 537 protein level variance. Pathway variability was calculated by averaging the biological variances of all 538 proteins annotated for a given ConsensusPathDB pathway. We required that each pathway contained at 539 least five quantified proteins. ConsensusPathDB combines pathway annotations from different sources. 540
Thus, in some cases the same pathway is reported more than ones. In such case the pathway variant with 541 the largest number of quantified proteins was used. 542 543
Determining the variance between tissues (inter-tissue variance) and between patients (inter-patient 544 variance) 545
Batch effects were corrected by centering each protein's concentration per batch. In our 546 experimental design, batches were balanced in the sense that each batch had the same number of benign 547 and malignant samples (3 of each) and each batch had the same number of samples from the same patient 548
(2 patients per batch, 3 samples from each patient). 549
Inter-tissue variances were estimated using concentrations centered per patient (subtracting 550 patient mean). Inter-patient variances were estimated using concentrations centered per tissue type 551 (subtracting tissue mean across patients). All of those computations were based on batch-corrected 552 concentrations and after averaging technical replicates. Batch-corrected values were also used for Figure  553 2. 554 555
Patient cohort and tissue microarray (TMA) 556
The Ethics Committee of the Kanton St. Gallen, Switzerland approved all procedures involving 557 human materials used in this TMA, and each patient signed an informed consent. For the study, patients 558 with BPH and matching ADCA were included, whereas advanced prostate cancer, infectious or 559 inflammatory diseases, or other malignancies fulfilled exclusion criteria as described previously (Cima, NUP93 were almost zero in the benign tissue samples. Thus, it is virtually impossible to estimate their 819 intra-tissue variation in benign tissues. The correlation between MS-based variance and TMA 820 homogeneity was however computed without excluding these two proteins. NUP93 was slightly off the 821 regression curve because its signal in IHC was relatively weak.
